Interest in paromomycin for the treatment of visceral leishmaniasis (kala-azar)

References

• WiwanitkitVSinghMYEmerging Infectious Diseases in IndiaNew YorkNova Publisher2008
   Google Scholar
• WiwanitkitVBone marrow leishmaniasis: a review of situation in ThailandAsian Pac J Trop Med201141075775922014727
   PubMed Web of Science ®Google Scholar
• AntinoriSSchifanellaLCorbellinoMLeishmaniasis: new insights from an old and neglected diseaseEur J Clin Microbiol Infect Dis201231210911821533874
   PubMed Web of Science ®Google Scholar
• GrimaldiGJrTeshRBMcMahon-PrattDA review of the geographic distribution and epidemiology of leishmaniasis in the New WorldAm J Trop Med Hyg19894166877252701633
   PubMed Web of Science ®Google Scholar
• GrimaldiGJrMcMahan-PrattDLeishmaniasis and its etiologic agents in the New World: an overviewProg Clin Parasitol19912731181893120
   PubMedGoogle Scholar
• HamiltonJGSandfly pheromones. Their biology and potential for use in control programsParasite200815325225618814690
   PubMed Web of Science ®Google Scholar
• DesjeuxPLeishmaniasis: current situation and new perspectivesComp Immunol Microbiol Infect Dis200427530531815225981
   PubMed Web of Science ®Google Scholar
• AlvarJYactayoSBernCLeishmaniasis and povertyTrends Parasitol2006221255255717023215
   PubMed Web of Science ®Google Scholar
• MarinkelleCJThe control of leishmaniasesBull World Health Organ19805868078186971184
   PubMed Web of Science ®Google Scholar
• HepburnNCCutaneous leishmaniasis: an overviewJ Postgrad Med2003491505412865571
   PubMedGoogle Scholar
• HepburnNCCutaneous leishmaniasisClin Exp Dermatol200025536337011012586
   PubMed Web of Science ®Google Scholar
• EnkCDGardloKHochbergMIngberARuzickaTCutaneous leishmaniasisHautarzt200354650651212759734
   PubMed Web of Science ®Google Scholar
• GuerinPJOlliaroPSundarSVisceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agendaLancet Infect Dis20022849450112150849
   PubMed Web of Science ®Google Scholar
• SinghRKPandeyHPSundarSVisceral leishmaniasis (kala-azar): challenges aheadIndian J Med Res2006123333134416778314
   PubMed Web of Science ®Google Scholar
• HerwaldtBLLeishmaniasisLancet199935491851191119910513726
   PubMed Web of Science ®Google Scholar
• AliALeishmaniases and HIV/AIDS co-infections: review of common features and management experiencesEthiop Med J200240Suppl 1374912802830
   PubMedGoogle Scholar
• VanlerbergheVDiapGGuerinPJDrug policy for visceral leishmaniasis: a cost-effectiveness analysisTrop Med Int Health200712227428317300636
   PubMed Web of Science ®Google Scholar
• MurrayHWProgress in the treatment of a neglected infectious disease: visceral leishmaniasisExpert Rev Anti Infect Ther20042227929215482193
   PubMedGoogle Scholar
• MatlashewskiGAranaBKroegerAVisceral leishmaniasis: elimination with existing interventionsLancet Infect Dis201111432232521453873
   PubMed Web of Science ®Google Scholar
• MondalSBhattacharyaPAliNCurrent diagnosis and treatment of visceral leishmaniasisExpert Rev Anti Infect Ther20108891994420695748
   PubMed Web of Science ®Google Scholar
• JhaTKDrug unresponsiveness and combination therapy for kala-azarIndian J Med Res200612338939816778318
   PubMed Web of Science ®Google Scholar
• OlliaroPLGuerinPJGerstlSHaaskjoldAARottingenJASundarSTreatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980–2004Lancet Infect Dis200551276377416310148
   PubMed Web of Science ®Google Scholar
• SundarSDrug resistance in Indian visceral leishmaniasisTrop Med Int Health200161184985411703838
   PubMed Web of Science ®Google Scholar
• OlliaroPLDrug combinations for visceral leishmaniasisCurr Opin Infect Dis201023659560220871400
   PubMed Web of Science ®Google Scholar
• MeheusFBalasegaramMOlliaroPCost-effectiveness analysis of combination therapies for visceral leishmaniasis in the Indian subcontinentPLoS Negl Trop Dis201049 pii:e818
   PubMed Web of Science ®Google Scholar
• van GriensvenJBoelaertMCombination therapy for visceral leishmaniasisLancet2011377976444344421255829
   PubMed Web of Science ®Google Scholar
• DubeASinghNSundarSSinghNRefractoriness to the treatment of sodium stibogluconate in Indian kala-azar field isolates persist in in vitro and in vivo experimental modelsParasitol Res200596421622315868188
   PubMed Web of Science ®Google Scholar
• LiuLXWellerPFAntiparasitic drugsN Engl J Med199633418117811848602186
   PubMed Web of Science ®Google Scholar
• Paromomycin preparationsJpn J Antibiot19833636446496348332
   PubMedGoogle Scholar
• SimonHJStreptomycin, kanamycin, neomycin and paromomycinPediatr Clin North Am196815173834866908
   PubMed Web of Science ®Google Scholar
• MössnerGTherapy of intestinal infections with paromomycinPharmakotherapia1964211491644960832
   PubMedGoogle Scholar
• MünchowPNew ready-made drugs. 9. Paromomycin “Jenapharm”Pharm Prax196592112135888291
   PubMedGoogle Scholar
• DavidsonRNden BoerMRitmeijerKParomomycinTrans R Soc Trop Med Hyg2009103765366018947845
   PubMed Web of Science ®Google Scholar
• KhanWKumarNCharacterization, thermal stability studies, and analytical method development of paromomycin for formulation developmentDrug Test Anal20113636337221698779
   PubMed Web of Science ®Google Scholar
• NyirjesyPSobelJDWeitzMVLeamanDJGeloneSPDifficult-to-treat trichomoniasis: results with paromomycin creamClin Infect Dis19982649869889564487
   PubMed Web of Science ®Google Scholar
• de la TribonnièreXValetteMAlfandariSOral nitazoxanide and paromomycin inhalation for systemic cryptosporidiosis in a patient with AIDSInfection199927323210378141
   PubMed Web of Science ®Google Scholar
• BissuelFCotteLde MontclosMRabodonirinaMTrepoCAbsence of systemic absorption of oral paromomycin during long-term, high-dose treatment for cryptosporidiosis in AIDSJ Infect Dis199417037497507915753
   PubMed Web of Science ®Google Scholar
• StaufferWRavdinJIEntamoeba histolytica: an updateCurr Opin Infect Dis200316547948514502002
   PubMed Web of Science ®Google Scholar
• WolfeMSThe treatment of intestinal protozoan infectionsMed Clin North Am19826637077206122766
   PubMed Web of Science ®Google Scholar
• BoteroDChemotherapy of human intestinal parasitic diseasesAnnu Rev Pharmacol Toxicol197818115348055
   PubMed Web of Science ®Google Scholar
• IwakiSHonkeKNishidaNTaniguchiNThe absorption, excretion and influence on bowel flora of oral paromomycin sulfate (author’s transl)Jpn J Antibiot1981347107810817321186
   PubMed Web of Science ®Google Scholar
• KanyokTPKillianADRodvoldKADanzigerLHPharmacokinetics of intramuscularly administered aminosidine in healthy subjectsAntimicrob Agents Chemother19974159829869145856
   PubMed Web of Science ®Google Scholar
• KhanWSharmaSSKumarNBioanalytical method development, pharmacokinetics, and toxicity studies of paromomycin and paromomycin loaded in albumin microspheresDrug Test Anal3222012 [Epub ahead of print.]
   Web of Science ®Google Scholar
• FourmyDYoshizawaSPuglisiJDParomomycin binding induces a local conformational change in the A-site of 16 S rRNAJ Mol Biol199827723333459514734
   PubMed Web of Science ®Google Scholar
• EusticeDCWilhelmJMMechanisms of action of aminoglycoside antibiotics in eucaryotic protein synthesisAntimicrob Agents Chemother198426153606433789
   PubMed Web of Science ®Google Scholar
• PirilaVRouhunkoskiSThe pattern of cross-sensitivity to neomycin. 51 cases of secondary sensitization to paromomvcin (Humatin)Dermatologica196212527327813943760
   PubMedGoogle Scholar
• KhanWKumarNDrug targeting to macrophages using paromomycin-loaded albumin microspheres for treatment of visceral leishmaniasis: an in vitro evaluationJ Drug Target201119423925020545446
   PubMed Web of Science ®Google Scholar
• ThakurCPKanyokTPPandeyAKSinhaGPMessickCOlliaroPTreatment of visceral leishmaniasis with injectable paromomycin (aminosidine). An open-label randomized phase-II clinical studyTrans R Soc Trop Med Hyg200094443243311127251
   PubMed Web of Science ®Google Scholar
• CroftSLOlliaroPLeishmaniasis chemotherapy – challenges and opportunitiesClin Microbiol Infect201117101478148321933306
   PubMed Web of Science ®Google Scholar
• MondalSBhattacharyaPAliNCurrent diagnosis and treatment of visceral leishmaniasisExpert Rev Anti Infect Ther20108891994420695748
   PubMed Web of Science ®Google Scholar
• JanvierFMorillonMOlliaroPVisceral leishmaniasis: clinical sensitivity and resistance to various therapeutic agentsMed Trop (Mars)20086818910118478781
   PubMedGoogle Scholar
• SundarSChakravartyJParomomycin in the treatment of leishmaniasisExpert Opin Investig Drugs2008175787794
   PubMed Web of Science ®Google Scholar
• CroftSLSundarSFairlambAHDrug resistance in leishmaniasisClin Microbiol Rev200619111112616418526
   PubMed Web of Science ®Google Scholar
• KulshresthaASinghRKumarDNegiNSSalotraPAntimony-resistant clinical isolates of Leishmania donovani are susceptible to paromomycin and sitamaquineAntimicrob Agents Chemother20115562916292121464251
   PubMed Web of Science ®Google Scholar
• BuffetPAGarinYJSulahianANassarNDerouinFTherapeutic effect of reference antileishmanial agents in murine visceral leishmaniasis due to Leishmania infantumAnn Trop Med Parasitol19969032953028758143
   PubMed Web of Science ®Google Scholar
• WilliamsDMullenABBaillieAJCarterKCComparison of the efficacy of free and non-ionic-surfactant vesicular formulations of paromomycin in a murine model of visceral leishmaniasisJ Pharm Pharmacol199850121351135610052848
   PubMed Web of Science ®Google Scholar
• ChungeCNOwateJPambaHODonnoLTreatment of visceral leishmaniasis in Kenya by aminosidine alone or combined with sodium stibogluconateTrans R Soc Trop Med Hyg19908422212252167522
   PubMed Web of Science ®Google Scholar
• JhaTKOlliaroPThakurCPRandomised controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in North Bihar, IndiaBMJ19983167139120012059583927
   PubMed Web of Science ®Google Scholar
• OlliaroPLGuerinPJGerstlSHaaskjoldAARottingenJASundarSTreatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980–2004Lancet Infect Dis200551276377416310148
   PubMed Web of Science ®Google Scholar
• SundarSAgrawalNAroraRAgarwalDRaiMChakravartyJShort-course paromomycin treatment of visceral leishmaniasis in India: 14-day vs 21-day treatmentClin Infect Dis200949691491819663597
   PubMed Web of Science ®Google Scholar
• CastroCMacêdoVSilva-VergaraMLEffectiveness of aminosidine sulphate in severe visceral leishmaniasis, resistant to the treatment with pentavalent antimonyRev Soc Bras Med Trop19952832732777480924
   PubMedGoogle Scholar
• SundarSJhaTKThakurCPSinhaPKBhattacharyaSKInjectable paromomycin for visceral leishmaniasis in IndiaN Engl J Med2007356252571258117582067
   PubMed Web of Science ®Google Scholar
• MusaAMYounisBFadlallaAParomomycin for the treatment of visceral leishmaniasis in Sudan: a randomized, open-label, dose-finding studyPLoS Negl Trop Dis2010410e85521049063
   PubMed Web of Science ®Google Scholar
• SinhaPKJhaTKThakurCPPhase 4 pharmacovigilance trial of paromomycin injection for the treatment of visceral leishmaniasis in IndiaJ Trop Med2011201164520322174722
   PubMedGoogle Scholar
• PandeyKDasVNSinghDPost-kala-azar dermal leishmaniasis in a patient treated with injectable paromomycin for visceral leishmaniasis in IndiaJ Clin Microbiol20125041478147922278840
   PubMed Web of Science ®Google Scholar
• OlliaroPSundarSAnthropometrically derived dosing and drug costing calculations for treating visceral leishmaniasis in Bihar, IndiaTrop Med Int Health2009141889219121150
   PubMed Web of Science ®Google Scholar
• OlliaroPDarleySLaxminarayanRSundarSCost-effectiveness projections of single and combination therapies for visceral leishmaniasis in Bihar, IndiaTrop Med Int Health200914891892519563434
   PubMed Web of Science ®Google Scholar
• MatlashewskiGAranaBKroegerAVisceral leishmaniasis: elimination with existing interventionsLancet Infect Dis201111432232521453873
   PubMed Web of Science ®Google Scholar
• BanerjeeADeMAliNCombination therapy with paromomycin-associated stearylamine-bearing liposomes cures experimental visceral leishmaniasis through Th1-biased immunomodulationAntimicrob Agents Chemother20115541661167021220536
   PubMed Web of Science ®Google Scholar
• BanerjeeADeMAliNComplete cure of experimental visceral leishmaniasis with amphotericin B in stearylamine-bearing cationic liposomes involves down-regulation of IL-10 and favorable T cell responsesJ Immunol200818121386139818606693
   PubMed Web of Science ®Google Scholar